InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
2
T+90 hit rate
100%
T+90 mean return
+15.1%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Renaud Ronald C JR, Chief Executive Officer. Insider active across 4 companies, notably Atara Biotherapeutics, Inc.. Cumulatively, 10 filings have been logged. Split: 1 buy · 2 sells. Total volume traded: €34.2m. Activity tracked since 8 June 2021. The latest transaction was filed on 3 August 2023 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations10 total
160,452 sharesCommon StockSEC:0000950170-24-090851:0
160,452 sharesCommon StockSEC:0000950170-23-072374:0
83,857 shares@ US$23.9552100.0% of flowCommon StockSEC:0000950170-23-039169:0
Ideal exit: 29 Apr 2024 (T+270)
20,500 shares0Common StockSEC:0001140361-22-024159:0
9,026 shares@ US$7.390.2% of flowCommon StockSEC:0001209191-21-056060
503,231 shares@ US$38.0049.8% of flowCommon StockSEC:0001209191-21-056062
503,231 shares@ US$38.0049.8% of flowCommon StockSEC:0001209191-21-056062:0
9,026 shares@ US$7.390.47% mcap0.2% of flowCommon StockSEC:0001209191-21-056060:0
11,000 shares0Common StockSEC:0001140361-21-020441:0
11,000 shares0Common StockSEC:0001140361-21-020441
10 of 10 declarations
About Renaud Ronald C JR
Ronald C. Renaud Jr. is the Chief Executive Officer of Atara Biotherapeutics, Inc. and Translate Bio, Inc. In these roles, he oversees the operations and growth strategy of the biopharmaceutical companies. Renaud brings extensive experience in the biotechnology sector, contributing to innovation and treatment research. His leadership is essential for achieving product development and commercialization objectives.
